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Increased PSA-based screening for prostate cancer has resulted in a growing number of
diagnosed cases. However, around half of these are ‘indolent’, neither metastasizing nor
leading to disease specific death. Treating non-progressing tumours with invasive therapies
is currently regarded as unnecessary over-treatment with patients being considered for con-
servative regimens, such as active surveillance (AS). However, this raises both compliance
and protocol issues. Great clinical benefit could accrue from a biomarker able to predict
long-term patient outcome accurately at the time of biopsy and initial diagnosis. Here we
delineate the translation of a laboratory discovery through to the precision development
of a clinically validated, novel prognostic biomarker assay (InformMDx™). This centres on
determining transcript levels for phosphodiesterase-4D7 (PDE4D7), an enzyme that breaks
down cyclic AMP, a signallingmolecule intimately connected with proliferation and androgen
receptor function. Quantifiable detection of PDE4D7 mRNA transcripts informs on the longi-
tudinal outcome of post-surgical disease progression. The risk of post-surgical progression
increases steeply for patients with very low ‘PDE4D7 scores’, while risk decreases markedly
for those patients with very high ‘PDE4D7 scores’. Combining clinical risk variables, such as
the Gleason or CAPRA (Cancer of the Prostate Risk Assessment) score, with the ‘PDE4D7
score’ further enhances the prognostic power of this personalized, precision assessment.
Thus the ‘PDE4D7 score’ has the potential to define, more effectively, appropriate medical
intervention/AS strategies for individual prostate cancer patients.
Prostate cancer
Prostate cancer is, worldwide, one of the most frequently diagnosed cancers in men above the age of 50
[1]. Its incidence is apparently increasing due to both a growing awareness of its occurrence in the elderly,
coupled with new possibilities for its early detection in asymptomatic phases [2]. When confined to the
prostate, invasive curative treatment by either surgical removal (radical prostatectomy) or radiotherapy
(brachytherapy or external beam) has excellent long-term results, with disease specific mortality <10%
in 10 years. Effectiveness is primarily dependent on the biologic aggressiveness of the tumour, expressed
as the Gleason grading, and on the local tumour stage. Low grade disease (Gleason score 3 + 3 = 6 or 3
+ 4 = 7 without cribriform patterns) [3] has a low growth rate and an extremely low risk of metastasis.
Though successful with regard to tumour control, invasive therapies can incur serious side effects such
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as incontinence, erectile dysfunction, radiation proctitis and urethral stenosis. These are evident in some 10–30% of
patients [4], incurring a major effect on Quality of Life. Thus, the risk of side effects from invasive therapy has to be
balanced against the potential gain in long-term survival.
Increased PSA-based screening has resulted in a growing number of diagnosed low-risk cancers. However, many of
these are regarded as ‘indolent’, are not expected tometastasize and are unlikely to generate tumour-related symptoms
during life [5]. In a population-based screening setting, these account for as many as 50% of all diagnosed cancers
[6]. Treating such asymptomatic tumours with invasive therapies can be regarded as unnecessary over-treatment.
Current, widely accepted guidelines propose actively following such patients up to their eighth decade, only offer-
ing invasive therapy where altered clinical signs suggest a change of biological behaviour from low to a higher risk
of future symptomatic disease. Clinically refraining from, or delaying, invasive therapy is called active surveillance
(AS). It is offered in order to protect from anymisinterpretation of the initial low risk tumour classification and detect
any altered growth towards a clinically more aggressive tumour status [7]. The criteria for reclassification towards a
higher risk follow the clinical experience of decades of tumour treatment where grading of Gleason Score 4 + 3 =
7 and a larger tumour volume are considered justification for invasive therapy to prevent later metastases. However,
apart from phenotypic clinical parameters, there is currently no validated prognostic biologic marker that represents
an early molecular signature able to signify an adverse course of a prostatic tumour. This is a major deficiency, as
tumour reclassification occurs in 40–50% of patients within 5 years of their starting on AS [8]. Currently, it is difficult
to predict effectively the clinical and biological behaviour of a tumour at the time of diagnosis. While MRI imaging
aids performing targeted biopsies in visible prostatic lesions, there is no clear imaging marker that can identify ad-
verse progression of such lesions [9]. Thus, clinicians and patients rely on histological analysis of repetitive biopsies.
This has compliance issues as it would appear that, both patients and physicians, tend to avoid biopsies over time,
notwithstanding their utility [10].
Current AS approaches, with a variety of protocols, lack sufficient follow-up to select; currently, an optimal strategy
for the safe, long-term surveillance of diagnosed prostate cancers. Thus, it would clearly be of great clinical benefit
to have an accurate biomarker able to predict the long-term outcome of cancers at the initial time of diagnosis and
biopsy. Such a novel biomarker would, undoubtedly, serve to reduce the number of men that shift towards invasive
therapy during the first 3–4 years of follow-up. In such a situation, a stratifying biomarker that identified a very low
risk group would be as important as one that indicated adverse progression. Stratification to a very low risk group
offers potential for heightened compliance by adjusting follow-upmethods to thosewithmuch fewer invasive biopsies
to perform over time. Furthermore, a biomarker that also highlighted signalling pathways relevant to future tumour
behaviour might provide a companion diagnostic for developing novel, targeted therapies.
Cyclic AMP phosphodiesterases
Cyclic 3′-5′ adenosine monophosphate (cAMP) was the first ‘second messenger’ to be described. It serves as the in-
tracellular manifestation of the binding of various hormones and neurotransmitters (‘first messengers’) to plasma
membrane-located receptors that are able to elicit increased cAMP generation through the activation of adenylyl cy-
clase via coupling to the GTP-binding protein, Gs [11,12]. Cell type specificity for particular first messengers thus
depends upon the types of Gs-coupled receptors that are expressed. The form of the cAMP signal (magnitude and
sustainability) is influenced by (i) the efficiency of receptor coupling to Gs, (ii) long- and short-term desensitization
processes acting at the receptor, (iii) the particular adenylyl cyclase isoform(s) expressed, (iv) signals acting on adeny-
lyl cyclase through the inhibitory G-protein (Gi) nexus and, of course (v) degradation of cAMP through the action
of cyclic nucleotide phosphodiesterases (PDEs) (Figure 1A) [13–15]. cAMP then exerts its action through binding
two main effector systems, namely, protein kinase A (PKA) whose activation engenders phosphorylation of target
proteins [11,12] and also through cAMP-binding Epac proteins that activate the ‘mini’ G-proteins, Rap1/2 [16].
As PDEs provide the sole route for intracellular cAMPdegradation and signal termination, they are poised to play a
pivotal role in regulating intracellular cAMP signalling. Activation of PDE enzymes leads to rapid signal termination
and desensitization, while their inhibition will confer either sustained signalling or even initiate signalling through
cAMP. Indeed, while manipulation of PDE activity provides a proven therapeutic approach, aberrant PDE activity
caused by genetically encoded mutations can underpin the underlying molecular pathology in various diseases.
The PDE superfamily consists of three cAMP specific (PDE4/7/8) members, three cGMP specific (PDE5/6/9)
members and five members that degrade both cAMP and cGMP (PDE1/2/3/10/11) [15,17–19]. While their cat-
alytic units show conservation, they are sufficiently different to allow selective inhibitors for each family to be
generated. These include PDE5-specific inhibitors, such as Viagra® (erectile dysfunction); PDE3 inhibitors, e.g.
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Figure 1. PDE4 isoforms and cAMP signalling cascades
(A) A schematic representation of PKA and EPAC effector protein mediated cAMP signalling cascades. The synthesis of cAMP by
the various adenylyl cyclase isoforms is influenced by the efficiency of GPCR coupling to stimulatory Gs or inhibitory Gi G-protein
α-subunits. The binding of cAMP to the regulatory subunits of PKA, or cAMP-binding domain of EPAC proteins, then leads to
the activation of downstream signalling events. The cAMP signal is constrained, or terminated, by the degradation of the cyclic
nucleotide through the action of cAMP phosphodiesterases (PDEs) such as PDE4 isoform variants. These isoforms exhibit distinct
subcellular localization patterns and regulate discreet pools of cAMP and compartmentalized signalling events. (B) A schematic
of PDE4 gene family and isoform structure. Four genes (PDE4A, green; PDE4B, gray; PDE4C, red; PDE4D, blue) encode multiple
isoform variants each of which are transcribed from independent promoter elements and express unique N-terminal regions. PDE4
isoforms can be separated into groups based upon their conserved domain structure where ‘long’ form PDE4 enzymes encode
both the UCR1 and UCR2 regulatory regions and ‘short’ isoforms express only UCR2, or a subsection thereof, in addition to the
core catalytic domain.
cilostamide (intermittent claudication) and PDE4 inhibitors as anti-inflammatory agents (e.g. roflumilast/Daxas®,
COPD; apremilast/Otezla®, psoriasis) and as cognitive enhancers.
There has beenmuch interest in the PDE4 family because of its potential as a therapeutic target [20], thatmutations
in PDE4D are associated with acrodysostosis [21] and that PDE4 gene linkages are associated with tumour develop-
ment including prostate cancer (PDE4D) [22], psychiatric illness (PDE4B) [23] and stroke (PDE4D) [24]. Further-
more, PDE4members play critical cellular roles in underpinning cAMP signalling compartmentalization within cells
[13]. This allows particular PDEs to control specific cellular processes by forming and shaping gradients of cAMP
around anchored cAMP effectors (PKA/Epac) to regulate their functioning. Additionally, PDE4 enzymes provide
nodes for integrating cross-talk with other signalling pathways via altered functioning elicited by post-translational
modification e.g. multisite phosphorylation, ubiquitination and SUMOylation triggered by other signalling pathways
[13,25].
Four PDE4 genes (A/B/C/D) encode over 20 distinct isoforms via distinct promoters coupled with alternative
mRNA splicing (Figure 1B) [25]. Each isoform is characterized by a unique N-terminal region that, invariably, con-
tains a ‘zip-code’ allowing isoform targeting to unique intracellular locations/complexeswhere it regulates local cAMP
levels. This allows particular isoforms to control specific intracellular processes [13,26]. Such gradients can be iden-
tified using FRET-based, genetically encoded cAMP sensors [27] and the functionality of anchored PDE4 species
interrogated by dominant negative approaches and disruption of anchoring [13].
Relatively little, however, is known about the processes and the intronic transcriptional modules underpinning the
cell type-specific expression patterns of the various PDE4 isoforms. However, certain isoforms have been shown to
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have CRE loci within intronic promoters that provide a feedback regulatory system by up-regulating the expression
of such PDE4 isoforms consequent to elevated cAMP levels causing CREB phosphorylation [28,29]. Conversely, a
novel cAMP-mediated transcriptional down-regulation of the PDE4A10 isoform occurs through a process involv-
ing the transcription factor, ICER (inducible cAMP early repressor) [30]. More studies are required to understand
the sophisticated array of processes that allow cell-type specific regulation of PDE4 isoform expression, dynamic re-
programming through various cell signalling processes, alterations in disease and intronic mutations that engender
pathological changes.
The catalytic unit of PDE4 isoforms comprises some 315 amino acids, which form three distinct subdomains and
is highly conserved between all subfamilies [25]. The catalytic site itself is located at the junction of these subdo-
mains with a deep substrate-binding cleft extending into subdomain-3. The nature of the catalytic site has allowed
for the generation of highly selective PDE4 inhibitors, while the similarities between PDE4 subfamilies have compro-
mised the generation of PDE4 subfamily specific inhibitors [20,25]. Attempts to generate PDE4 subfamily specific
inhibitors are also complicated by the fact that the structure of full-length PDE4 isoforms in cells can be affected
by post-translational modifications and interaction with partner proteins. Thus, ‘physiological structures’ will un-
doubtedly differ considerably from those of the purified truncated catalytic unit constructs invariably used in drug
development programmes.
In vivo, the functioning and conformation of the catalytic unit is determined by two highly conserved regula-
tory units located at N-terminal of the catalytic unit (Figure 1B) [20,25]. These are the 60-amino acid UCR1 and
the 80-amino acid UCR2 that are found in PDE4 ‘long’ isoforms, where they interact with each other, providing a
module that mediates the action of regulatory multisite phosphorylation and drives dimerization [31–33]. In con-
trast, ‘short’ PDE4 isoforms lack UCR1 and, as a consequence are monomeric, and demonstrate different regulatory
phosphorylation responses [31].
PDE4 isoforms are universally expressed and have undergone evolutionary expansion to provide a library of sophis-
ticated regulatory species serving specific roles in different cell types. As such, alterations in their activity, expression,
regulation and targeting in health and disease may lead to marked functional consequences. Here we discuss how
following transcript levels of the long PDE4D7 isoform provides a novel prognostic indicator to select the optimal
strategy for a long-term surveillance of diagnosed cancers of the prostate.
cAMP and prostate cancer
cAMP-mediated signalling pathways were first implicated as playing a role in prostate cancer when Shima et al. [34]
reported a differential expression of adenylyl cyclase in rat prostate lesions. Since that time cAMP signalling has
been shown to transactivate the androgen receptor, regulate androgen sensitive transcription and underpin neuroen-
docrine differentiation in the prostate. Furthermore, the principle cAMP effector proteins, namely protein kinase
A (PKA) [35–37] and EPAC1/2 [38], have been directly implicated in aberrant molecular signalling pathways that
support the growth of cancerous lesions.
Protein kinase A
PKA is the archetypal effector protein kinase that is directly activated by cAMP and underpins many of the ac-
tions linking cAMP signalling to the progression of prostate cancer [39]. PKA is a heterotetrameric enzyme com-
posed of two regulatory subunits (R) and two catalytic kinase subunits (C), where the regulatory subunits, either
RIα/RIβ/RIIα/RIIβ, bind directly to the cognate catalytic subunits, either Cα/Cβ/Cγ, which they constitutively in-
hibit. Binding of cAMP to the R-subunits in this complex releases the activated catalytic unit, which then goes on
to phosphorylate various target proteins that are expressed in a cell-type specific manner. The regulation of these
signalling events is underpinned by the compartmentalization of cAMP nanodomains by cAMP degrading PDEs
coupled with the targeted localization of PKA through interaction with anchor proteins [11–13,26,27]. Changes in
cellular PKA distribution, expression and activity have all been shown to contribute to the aberrant proliferation of
prostatic tissue [39]. Indeed, the up-regulation of PKA-Cβ2 has been connectedwith aberrant proliferation in prostate
cancer, while altered Cβ3 and Cβ4 expression influences neuroendocrine differentiation, key regulating factors in
prostate cancer progression [40]. The up-regulation of PKA RI sub-units has also been associated with aggressive
prostate cancer [41].
Themore recently discovered EPAC proteins provide a second group of cAMP effector proteins. These bind cAMP
to undergo a conformational change that facilitates their role as GEFs for the activation of GTPases Rap1 and Rap2
[16,38]. Evaluation of EPAC proteins in prostate cancer progression is in its infancy. However, EPAC1 can potentiate
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cell proliferation and regulate cellular adhesion [16,42,43] and, Rap1 is associated with metastatic potential in the
prostate [44] and mediates the synergism between cAMP and EGF signalling in prostate cancer [45].
The convergence of androgen and cAMP signalling
Androgen signalling is central to the initial proliferative drive and the outgrowth of prostate tumours, and is there-
fore targeted in the mainstay prostate cancer treatments [46]. However, cAMP signalling is closely tied to androgen
receptor activity, not only modulating androgen synthesis by mediating the downstream signalling events associated
with the action of luteinizing hormone, but also by impacting on androgen receptor signalling itself. Furthermore,
cAMP plays a role in regulating ligand-independent activation of the androgen receptor that occurs in response to
the activation of NF-B and Rho signalling cascades [47–49].
As well as playing a role in regulating androgen receptor activity, cAMP can alsomodulate the co-operative binding
of transcription factors at androgen response elements within gene promoters. This was uncovered when PSA, the
archetypal androgen responsive gene and prostate cancer biomarker, was identified as increasing upon treatment of
prostate cancer cells with forskolin, a direct activator of adenylyl cyclase [50]. PKA phosphorylation of the transcrip-
tion factor CREB confers interaction with its protein partners, p300 and CBP. These are KAT3 family of proteins,
which act as lysine (K) acetyl transferases (KAT) able to modify histones and non-histone proteins, thereby regu-
lating chromatin accessibility and transcription. In particular, they exert a synergistic action on androgen sensitive
signalling [51,52].
Neuroendocrine (NE) cells are found in the lumen of the healthy prostate and secrete a variety of signalling
molecules including chromogranin A, vasoactive intestinal peptide and vascular endothelial growth factor [53–55].
The NE differentiation of epithelial cells within prostatic tumours is well-documented and thought to result in the
elevated incidence of these cells in biopsies from advanced cases of prostate cancer. An increased level of such
trans-differentiated cells can occur after prolonged androgen deprivation therapy and is associated with elevated
serum levels of both chromogranin A and neurone-specific enolase: markers of NE cell types. Indeed, prostatic tu-
mours can nucleate around colonies of neuroendocrine-like cells during androgen withdrawal therapy with the as-
sociated secretory neuroendocrine products stimulating the proliferation of prostatic epithelial cells [56,57]. This
reflects the formation of cAMP-regulated, paracrine and autocrine signalling loops associated with the progression
of prostate cancer [58–60]. In vitro, NE differentiation can be stimulated in androgen-sensitive cells by either andro-
gen withdrawal or, importantly, by increased cAMP signalling [61]. This highlights further the notion that increased
cAMP signalling in prostate cancer cells leads to disease advancement and a poor prognosis.
PDE expression in prostate cancer: the importance of
PDE4D7
PDEs provide the sole means for the degradation of cAMP. As such they are poised to provide a key regulatory role.
Thus, aberrant changes in their expression, activity and intracellular location may all contribute to the underlying
molecular pathology of particular disease states. Indeed, it has recently been shown that mutations in PDE genes are
enriched in prostate cancer patients leading to elevated cAMP signalling and a potential predisposition to prostate
cancer [62].However, varied expression profiles in different cell types coupledwith complex arrays of isoform variants
within eachPDE familymakes understanding the links between aberrant changes in PDE expression and functionality
during disease progression challenging. Several studies have endeavoured to describe the complement of PDEs in
prostate, all of which identified significant levels of PDE4 expression alongside other PDEs. In particular, Uckert et al.
[63] not only identified transcripts for PDE1A, PDE1B, PDE2A, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A, PDE7A,
PDE8A, PDE9A and PDE10A within prostate tissues, but also showed that PDE4, PDE5 and PDE11 enzymes were
each localized to distinct prostate compartments [64].
Using sequence information on currently identified PDE isoforms, we profiled PDE superfamily member expres-
sion in 19 prostate cancer cell lines and xenografts [65]. Our studies identified PDE3B, PDE4B, PDE4D, PDE7A,
PDE8A, PDE8B and PDE9A isoforms as being abundantly expressed at the mRNA level in cancerous prostate cells
[65], while PDE1, PDE3A, PDE5A, PDE10A and PDE11A mRNA are present at lower levels (unpublished data),
highlighting the complexity of cyclic nucleotide signalling in the prostate epithelium. Importantly, by separating the
prostate cancer cell samples into androgen sensitive and androgen insensitive, castration resistant prostate cancer
(CRPC), cellular phenotypes, we discovered that the expression of PDE4D isoforms was down-regulated in CRPC
samples. In particular, we found that the most abundant PDE4 isoform in many of the androgen sensitive samples,
PDE4D7, exhibited a significant degree of down-regulation in the CRPC cell models, presenting a scenario where
the down-regulation of PDE4D7 could directly contribute to the exacerbation of disease driving cAMP signalling
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changes. Moreover, these observations suggested that measurement of PDE4D7 had potential to inform on prostate
cancer disease progression where low levels of PDE4D7 expression may be connected with a more aggressive pheno-
type.
The intracellular function and regulation of PDE4D7
While changes in the expression level of mRNA transcripts can be utilized as a disease biomarker, understanding the
biological outcome or function of these changes builds confidence in how the target is integrated with the underlying
disease.
PDE4D7 is characterized by its unique 80 amino acid N-terminal region [66]. It is a so-called ‘long’ PDE4 isoform
by virtue of it having both the UCR1 and UCR2 regulatory domains [25]. These, and the catalytic unit, can be subject
to multisite phosphorylation by various protein kinases, which allows PDE4D7 to integrate inputs from other sig-
nalling pathways as well as for feedback activation by cAMP signalling through PKA phosphorylation of a conserved
serine (Ser129) within UCR1 [13]. As with other PDE4 isoforms [13], the unique N-terminal region of PDE4D7 is
involved in intracellular targeting to distinct intracellular locales, which are critical for the particular functionality of
this isoform [65]. An insight into functionality was gained using the exemplar androgen-sensitive (VCaP) and CRPC
(PC3) cell lines, where the differences in mRNA abundance are translated at protein level with the level of cAMP
PDE4D7 activity being significantly reduced in the CRPC cancer cell line.
A major fraction of PDE4D7 is localized to the plasma membrane where it has a major influence on sub-plasma
membrane cAMP dynamics detected using a targeted, genetically encoded FRET-based cAMP sensor. Thus PDE4D7
can exert effects on a discrete cAMP ‘pool’ / compartment in cells, indicating that it will have a defined functionality, in
this case inmodulating cellular proliferation. Thiswas exemplified by (i) a dominant negative strategy, where displace-
ment of PDE4D7 from its functionally important membrane site is achieved by overexpression of a catalytically inac-
tive PDE4D7 mutant, and (ii) by siRNA-mediated knockdown. Both strategies elicited enhanced androgen-sensitive
cellular proliferation. Conversely, overexpression of exogenous PDE4D7, in CRPC PC3 cells, suppressed their prolif-
eration by increasing PDE4D7 levels,.
The PDE4D7 promoter has been identified with initial studies identifying multiple CREB binding sites (CRE
loci), suggesting that the cAMP/PKA signalling pathway may regulate PDE4D7 transcriptional expression [65]. Oth-
erwise, little more is known, save that susceptibility markers for ischaemic stroke map to the region of Chr5q12
where PDE4D7, and the overlapping androgen-sensitive PART1 exons, locate [24,65–68].
Functional studies give insight into how down-regulation of PDE4D7 may impact on the progression of prostate
cancer. It must also be noted, however, that pan-PDE4 and PDE4D-selective inhibitors have been reported to sup-
press the growth of some prostate cancer cell models [69]. These reports suggest the importance of isoform-specific
signalling events where the inhibition of additional isoforms, alongside PDE4D7, may affect the initial cellular re-
sponse to modulation of PDE4 activity. Recently, a large-scale genome wide investigation [22] also indicated that
genetic aberration of the PDE4D locus is a common feature of prostate cancer where early loss of heterozygosity or
homozygous deletion of the PDE4D/IL6ST locus in aggressive disease imparts a cancer-suppressive role. In this con-
text, the activity of PDE4D7 may allow for the modulation of cAMP signalling events in early prostate cancer that is
lost during its down-regulation, thereby allowing for a more aggressive prostate cancer phenotype. Such mechanistic
insights into the purported role of PDE4D7 in the progression of prostate cancer provide functional underpinning
for the potential use of using PDE4D7 transcript levels as a biomarker for prostate cancer progression.
Translation of the tissue marker PDE4D7 into a clinical
application
Verification of the results generated during the discovery phase
Biomarker validation presents a typical ‘chicken and egg’ situation. Ideally, the first step is to develop a robust, sen-
sitive, efficient and reproducible assay for the biomarker of interest that will work with high integrity using various
tissue materials, such as cDNA and total RNA isolated from either fresh, frozen or formalin-fixed tissue sections.
Translating this, from the initial research observation, takes a considerable investment in terms of both time and
money under conditions when it is not known whether the proposed marker will have value in a clinically relevant
patient cohort. Rather than immediately recruiting patients to assess, an alternative approach is, firstly, to analyse
publically available data sets. These can be interrogated regarding the expression of the proposed biomarker in order
to try and uncover potentially useful correlates. Such a pure ‘in silico’ approach has a potential disadvantage in that,
often, the clinical annotation associated with publically available data sets is limited. Furthermore, in many instances,
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it is unclear as to how the respective patient samples were collected. Often this is done on an ‘availability and access’
basis, which makes it difficult to determine how much bias comes with the data. In order to control this more ef-
fectively, material collected prospectively from a consecutively managed patient cohort is required. This demands a
major resource commitment, especially in situations where the clinical value of the proposed biomarker remains to
be proven.
In developing PDE4D7 expression as a prognostic biomarker for prostate cancer, we adopted a hybrid development
path, taking the initial laboratory observations through to clinical utility using a combination of primary research
and re-analysis of existing public gene expression datasets [65,70–73]. Firstly we developed an effective bio-assay for
PDE4D7 that, in its early form, was sufficient for validation and assessment of clinical utility. Secondly, we conducted
an in silico analysis of PDE4D7 expression across publicly available prostate cancer data sets. The first clinical valida-
tion analysis used data from eight different publically available databases represented a total of 1405 patients across a
multitude of different clinically relevant prostate disease states [73]. These data sets represented tumour states in terms
of their tissue representation where normal adjacent prostate (NAP), benign lesions (BL) and hyperplasia (BPH) of
the prostate were detailed alongside primary prostate cancer (Primary PCa) with various levels of post-surgical dis-
ease progression (none, progression to biochemical relapse, progression to metastases), as well as metastatic prostate
cancer and hormone-refractory CRPC (castration resistant prostate cancer). Five DNA Exon array datasets (1006
samples in total) were interrogated with probe sets specific for PDE4D7 and the RNAseq data available via the TCGA
consortium (193 samples in total) were analysed for PDE4D7 expression using isoform specific sequencing reads.
Such DNAmicroarray and RNAseq data were then normalized using standard methodologies (e.g. RMA or FPMK).
In parallel to the in silico analysis, two of the data sets (206 samples in total) were investigated using an early devel-
opment of our RT-qPCR assay for PDE4D7 using an initial set of reference genes for normalization [73].
Data generated during these studies provided multiple important insights. Crucially, we confirmed, in a clini-
cal setting [73], our initial, laboratory-based hypothesis derived from observations on prostate cancer cell lines and
xenografts [65]. Namely that PDE4D7 was significantly down-regulated in tumours presenting aggressive character-
istics associated with reduced androgen dependency (Figure 2A). This was a critical, convincing verification given
that we obtained similar results across independent data sets. Thus, we showed that PDE4D7 measurement informs
on the progression of prostate cancer regardless of the bias of sample collection, unknown clinical patient character-
istics and other potentially confounding factors. Furthermore, our early stage RT-qPCR assay delivered reproducible
data across two independent sample sets where we analysed PDE4D7 expression in normal adjacent tissue (NAP)
versus primary cancer tissue (tumour; Figure 2B). Such data allowed comparable conclusions to those obtained from
our analyses of DNA Exon microarray data sets (Figure 2B). Finally, we showed that, across multiple datasets, re-
duction in normalized expression of PDE4D7 mRNA is associated with adverse pathology outcome in terms of the
post-operative Gleason score (Figure 2C). This allowed us to further propose [73] that PDE4D7 down-regulation in
prostate cancer is associated with longitudinal biological outcome after primary intervention (Figure 2D).
An additional outcome of our validation studies was the demonstration that, despite the complexity of transcrip-
tion and splicing associated with PDE4 isoform regulation, it is possible to both detect and quantify individual PDE4
transcripts from DNA Exon microarray, next-generation RNAseq and RT-qPCR approaches. Having developed the
technical tools necessary to quantify individual PDE4D transcripts, and leverage the statistical power of the different
sources of available ‘–omics’ data, we thought it prudent to determine whether tumorigenesis of the prostate leads to
additional changes in PDE4D transcript expression profile or whether changes were unique to PDE4D7. In partic-
ular, we wanted to build on our original cell line and xenograft study [65] and understand which PDE4D isoforms
are expressed in prostate cancer tissue and whether there are selective, disease-associated changes in PDE4D iso-
form expression concerning the known short (PDE4D1, PDE4D2, PDE4D6) forms and the long (PDE4D3, PDE4D4,
PDE4D5, PDE4D7, PDE4D8 and PDE4D9) forms and if this might provide a multifactorial signature for PDE4D ex-
pression in prostate cancer. In line with the PDE4D isoform expression pattern that we observed in the initial cell line
and xenograft studies [65], across the clinical data sets we found evidence for consistent transcription of PDE4D1 and
PDE4D2 short forms as well as clear evidence of consistent transcription of PDE4D5, PDE4D7 and PDE4D9 [72,73].
Inconsistent expression patterns were noted for the other long forms of PDE4D [72]. Consequently, we focused our
attention on the analysis of the PDE4D1 and PDE4D2 short isoforms and the PDE4D5, PDE4D7 and PDE4D9 long
forms.
TMPRSS2-ERG-positive tumours and PDE4D7 expression
The prostate cancer-specific TMPRSS2-ERG gene fusion event occurs in approximately 50% of prostate cancer pa-
tients and has become recognized as a molecular hallmark of prostatic tumourigenesis [74]. This occurs between the
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Figure 2. PDE4D7 expression in prostate cancer
(A) Expression of PDE4D7 Splice Variant in Prostate Tissues. Annotations: ‘Primary PCa NP’ – primary prostate cancer, no post–
surgical progression; ‘primary PCa BCR’ – primary prostate cancer, post-surgical progression to biochemical recurrence (BCR);
‘primary PCa CR’ – primary prostate cancer, post-surgical progression to clinical recurrence (CR); Metastases – metastatic prostate
cancer tissue; CRPC – castration resistant prostate cancer tissue. (B) Expression of PDE4D7 Splice Variant in Normal, Benign ver-
sus Cancerous Prostate Tissues. Annotations: NAT – normal adjacent tissue; BL – benign prostate lesions; BPH – benign prostate
hyperplasia lesions; Tumour – prostate cancer with various Gleason grades. (C) Correlation of PDE4D7 Expression to Pathology
Gleason Score. Annotations: BCR – post-surgical progression to biochemical recurrence (-/+ = no/yes). TMPRS2-ERG – status of
the gene fusion between the TMPRSS2 and the ERG genes (-/+ = no/yes). pGleason – pathology Gleason score after surgery. (D)
Kaplan–Meier survival curves in men with biochemical recurrence after primary treatment. Using a cut-off of <0.51 (corresponding
to the Youden-Index) for normalized PDE4D7 expression, two patient cohorts can be separated with a median time to biochemical
recurrence (BCR) after primary treatment of 9.9 and 9 months versus a median time to BCR of 30.6 and 50 months, respectively
(HR = 0.29; P = 6.0E-04; HR = 0.36; P = 1.6E-03, respectively). Significant P-values of group comparison are indicated (**P<0.01;
***P<0.001). Figures and legends are adapted from reference [73].
5′ untranslated region of TMPRSS2 (transmembrane protease, serine 2), an androgen-regulated gene and the ETS
transcription family member, ERG. It leads to a deletion of an interstitial chromosomal region containing 16 genes
on chromosome 21, by either complete deletion or by chromosomal translocation of this interstitial area to another
region of chromosome 21. This event was identified by an outlier approach as it does not occur in all prostate tu-
mours [74]. Subsequently, it was found that other ETS transcription factor family members can be found fused to the
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TMPRSS2 gene in prostate cancer, namely ETV1, ETV4 and ETV5, although at typicallymuch lower prevalence com-
pared with the TMPRRS2-ERG rearrangement [75]. Interestingly, we identified a distinct expression pattern for the
individual prostate cancer relevant PDE4D transcripts in five patient cohorts where we had access to information on
their TMPRRS2-ERG status [72]. Importantly, in contrast with PDE4D5, PDE4D9, PDE4D1 and PDE4D2, transcript
levels of PDE4D7 were found at a significantly higher level in TMPRRS2-ERG positive cancers compared with fusion
gene negative prostate cancers (Figure 3A). Further analysis revealed that when PDE4D transcript levels were com-
pared between primary TMPRSS2-ERG positive tumours and adjacent normal tissue (NAP), we not only observed
PDE4D7 up-regulation but also found that the other evaluated PDE4D transcripts were down-regulated [72,73].
Such observations uncovered a context-dependent pattern of events where PDE4D7 exhibits a unique up-regulation
of expression in TMPRSS2-ERG positive tumours versus NAP [72,73]. However, in contrast with this, the striking
down-regulation of PDE4D7 is clearly correlated with a more aggressive tumour phenotype (Figure 3B) [72,73].
The basis and functional significance of PDE4D7 up-regulation in the presence of the TMPRRS2-ERG gene fusion
remains to be determined. However, the effect is clearly specific for the fusion of the ERG transcription factor as we
did not find the same PDE4D7 up-regulation where TMPRSS2 was fused to ETS transcription factors other than
ERG, namely either ETV1 or ETV4 [72]. Presumably, PDE4D7 up-regulation is due either directly or indirectly to
the increased expression of the ERG gene, which is driven by androgen-stimulated transcription of the TMPRSS2
gene [74,76].
Very recently, differences in the genomic evolution of TMPRRS2-ERG gene fusion positive tumours compared
with tumours without such a gene rearrangement have been uncovered from whole genome sequencing (WGS) of a
total of 112 primary and local/distant metastatic prostate cancers [22]. This indicated that the earliest homozygous
deletions appeared on Chr5 in the region 55–59Mb in fusion positive tumour tissues while, in ERG negative cancers,
the losses emerged in the region 60–100 Mb on the same chromosome. Intriguingly, it is the region between 59 and
60 Mb on Chr5 that encompasses the exons and the promoters of both PDE4D7 and PDE4D5. How this might affect
the differential expression of PDE4D transcripts remains to be ascertained. However, it is striking that the breakpoint
in genomic losses on Chr5, in either the presence or absence of the TMPRRS2-ERG gene fusion, occurs within the
putative promoter and transcriptional start regions of long PDE4D isoforms whose expression is altered in prostate
cancer.
Early insights into prostate cancer-regulated transcription of PDE4D
isoforms
In order to assess potential involvement of transcriptional regulation of PDE4D transcripts by either the ERG tran-
scription factor or by the ARwe interrogated a ChiP-seq dataset generated from a prostate cancer cell line treated with
the synthetic androgen R1881 [77]. With ChiP-seq, proteins binding to genomic DNA are cross-linked, followed by
precipitation of the protein of interest, namely ERG and AR in this case, using selective antibodies. The cross-linked
DNA is then sequenced allowing the identification of DNA sites to which the protein of interest has bound. This ap-
proach identified a multitude of putative binding sites for the AR, as well as for the ERG transcription factor, within
the PDE4D gene locus. Some of these were found to overlap partially with the first, isoform-specific exon of each of
the long isoforms PDE4D5, PDE4D7 and PDE4D9 [72]. Subsequent analysis confirmed that there was very strong en-
richment for both putative AR and ERG binding sites compared with randomly selected genomic regions of the same
size as the PDE4D gene (approximately 1.5 Mb) across all chromosomes [72]. Coupled with the fact that PDE4D7
exons overlap with those of the androgen regulated gene PART1, these results support the view that both androgen,
as well as the ETS transcription factor ERG, are involved in the regulation of the PDE4D gene locus.
DNA methylation plays a key role in transcriptional regulation and has been evaluated in the context of prostate
cancer based diagnosis [78,79]. Themethylation of promoter regions of particular genes leads to their transcriptional
repression [80]. In cancer CpG-rich regions of gene promoters can undergo aberrant hypermethylation, leading to
the silencing of gene expression [81]. Evaluating various DNA methylation data sets generated from prostate cancer
tissues, we noted [72] that hypermethylated patterns were consistently identified for five PDE4D transcripts, namely
PDE4D1, PDE4D2, PDE4D4, PDE4D5 and PDE4D8 and that, in some cases, these regions included the transcrip-
tional start sites (TSS) of such PDE4D isoforms. To elucidate the impact of the hyper-methylated regions of PDE4D
gene we compared PDE4D transcript levels recorded in DNAmicroarray datasets, with patient matched methylation
data [72]. From this information we calculated Spearman’s correlation coefficient and found that PDE4D5 showed
the strongest negative correlation (r = −0.57) between the extent of TSSmethylation and transcript expression. Thus
it may be that differential methylation is relevant for the regulation of the expression of some, but clearly not all,
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Figure 3. PDE4D7 expression and TMPRSS2-ERG gene fusion status
(A) Correlation of PDE4D7 Expression in Normal and Cancerous Human Prostate Tissues to TMPRSS2-ERG Gene Fusion Sta-
tus. Samples were divided into three different groups: (1) normal adjacent tissue without TMPRSS2-ERG fusion events (NAT TM-
PRSS2-ERG negative); (2) prostate tumour tissue without TMPRSS2-ERG fusion events (Primary PCa, TMPRSS2-ERG negative)
and (3) prostate tumour tissue with TMPRSS2-ERG fusion events (Primary PCa, TMPRSS2-ERG positive). (B) PDE4D isoform ex-
pression in prostatic tissues. Annotations: CR – clinical recurrence, BCR – biochemical recurrence, CPRC – castration resistant
prostate cancer. Significant P-values of group comparison for difference of mean PDE4D7 expression are indicated (*P<0.05).
Figures and legends are adapted from references [72,73].
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PDE4D isoforms expressed in prostate tissue. Certainly, it would appear that PDE4D7 expression is not regulated by
methylation and, in this regard, PDE4D7 and PDE4D5 show opposing expression behaviour in prostatic tissue.
The data generated by this hybrid approach to the validation of PDE4D7 as a prognostic biomarker of prostate
cancer reinforced the strong link between PDE4D7 expression and the aggressiveness of prostatic cancer and proved
to be sufficiently convincing to allow us to progress to the next stage of clinical validation.
Validation within a clinical setting
The translation of a laboratory-based proposal for a disease-relevant biomarker into a clinical setting requires the
development of a robust and accessible assay for the gene of interest as well as its rigorous evaluation in a multi-
tude of different patient cohorts and settings. Therefore, a suitable assay technology that enables the sensitive and
reproducible measurement of the relevant biomarker needs to be developed. Despite enormous progress in the devel-
opment of gene expression platform technologies, such as DNA microarrays and next-generation RNA sequencing,
the technology chosen for data validation and the development of a specific, reproducible, assay remains quantitative
PCR (qPCR). This is because it provides a robust and affordable means for assessing virtually any defined transcript.
Furthermore, this assay not only is able to work on freshly isolated nucleic acids, but also can function effectively us-
ing formalin-fixed, paraffin embedded tissue, which is routinely generated in the clinic. Additionally, this approach
allows the straightforward selection of appropriate reference genes for use in the normalization of the biomarker ex-
pression across various sample preparations. However, while multiple reference genes might increase robustness, this
will also increase the assay complexity.
In order to streamline the assays for commercial use, the qPCR assay has to be developed from amultistage protocol
into a one-step RT-qPCR assay where the RNA startingmaterial is reverse-transcribed and assayed in a single reaction
step. Similarly, data quantification and assay processing require automation, aligning the procedure to translate raw
data intoCq values that represent the normalized expression value of the biomarker transcript which is then evaluated
using a pre-defined ‘quality’ metric in order to determine which data elements are robust, and which outliers should
be discarded from downstream statistical analysis. Most importantly, a concept of how to interpret the data in order
to provide a result of clinical value needs to be defined and executed.
Undertaking further optimization and testing of the PDE4D7 RT-qPCR assay, we were able to generate a robust
and sensitive assay with very high target specificity and a high sensitivity of target detection (the limit of detection is
close to 1 copy of RNA in FFPE, formalin-fixed, paraffin embedded tissue). In its final form this sensitive assay had a
high level of assay efficiency (close to 100%), assay linearity over a range of target concentrations (R2 > 0.98) as well
as high levels of assay reproducibility (technical replicates SD < 0.3 Cq).
We then set out to identify an appropriate set of reference genes. A range of ten candidate reference genes that are
commonly used in qPCR studies were used to evaluated PDE4D7 transcript levels in human prostate FFPE samples
as well as a number of cell lines. From these studies we chose PUM1, TBP, TUBA1B and HPRT1 as the most stable
reference genes for evaluating PDE4 transcripts in prostatic tissue [71]. In order to ensure robust data quality we
pre-defined a Cq threshold to either accept or refuse a sample for downstream data analysis. The selected threshold
was based on the analysis of qPCR data on FFPE tissue extracted RNA of known concentrations from which we
deduced a Cq threshold value as the limit of detection of a single copy of RNA in the sample [71].
Regarding normalization of PDE4D7 Cq values, we used a modified Cq approach by subtracting the Cq mean of
the four selected reference genes from the PDE4D7 Cq value of each tumour sample. Thus, we generated a normal-
ized PDE4D7 expression value with a normal distribution between −8 and +4 [71]. Subsequently, we translated the
normalized expression values by linear transformation into a +1 to +5 distribution. This provides a ‘PDE4D7 score’
which relates to PDE4D7 abundance and is categorized into four groups: (1) all PDE4D7 scores between 1 and <2;
(2) all PDE4D7 scores between 2 and <3; (3) all PDE4D7 scores 3 and <4; (4) all PDE4D7 scores between 4 and 5
[71].
Based on the correlation between PDE4D7 expression and pathological features of the disease, our defined aimwas
to identify prognostic associations between the expression of PDE4D7 in a patient prostate tissue, collected by either
biopsy or surgery, and clinically useful information relevant to the outcome of individual patients. Clinically relevant
endpoints, or surrogate endpoints that are significantly correlated to the development of metastases, cancer specific
or overall mortality have, typically, been evaluated as prognostic cancer biomarkers [82]. The most relevant rational
for using a surrogate endpoint relates to situations where either data on established clinical endpoints are not available
or when the number of events in the data cohort is too limited for statistical data analysis. For the development of the
PDE4D7 prognostic biomarker, we evaluated either BCR (biochemical relapse) progression-free survival or the start
of post-surgical secondary treatment as surrogate endpoints for metastases and prostate cancer death. Using these
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particular endpoints, we identified a relevant number of events in our clinical cohorts (e.g.>30% for BCR), which is
particularly relevant for multivariable data analysis [83].
In our evaluation, we selected standardmethods ofmultivariable analysis such asCox regression andKaplan–Meier
survival analysis in order to investigate the added and independent value of the continuous and/or the categorical
‘PDE4D7 score’ compared with established prognostic clinical variables such as PSA and Gleason score [71]. We
thus built risk models where we combined the ‘PDE4D7 score’ with either pre- or post-surgical clinical predictors
of post-surgical progression using logistic regression. The resulting models were subsequently tested on multiple
independent patient cohorts in Kaplan–Meier survival and ROC curve analysis in order to predict post-treatment
progression free survival [71].
Using such a strategy, we set out to test the prognostic value of the PDE4D7 score on a biopsy from retrospec-
tively collected, resected prostate tissue in a consecutively managed patient cohort from a single surgery centre in a
post-surgical setting [71]. The patient population comprised some 500 individuals where longitudinal follow-up, of
both pathology and biological outcomes, was undertaken. These clinical data were available for all patients and col-
lected during a follow-up of a median 120 months after treatment. The ‘PDE4D7 score’ was determined as described
above and then tested in both uni- andmultivariable analyses using the available post-surgical co-variates (i.e. pathol-
ogy Gleason score, pT stage, surgical margin status, seminal vesicle invasion status and lymph node invasion status)
in order to adjust for the multivariable setting. In this instance, biochemical progression-free survival after primary
intervention was set as the evaluated clinical endpoint. The univariable analysis of these clinical samples [71] show-
ing the inverse association between PDE4D7 expression (in terms of ‘PDE4D7 score’) and post-surgical biological
relapse (HR= 0.53 per unit change; 95% CI 0.41–0.67; P<0.0001), robustly confirmed our previous data [65,71–73].
In multivariable analysis with such clinical variables, the ‘PDE4D7 score’ remained as an independent and effective
means for predicting clinical outcome (HR = 0.56 per unit change; 95% CI 0.43–0.73; P<0.0001). Furthermore, we
obtained [71] a very similar outcome when we evaluated the ‘PDE4D7 score’ in multivariable analysis (HR = 0.54
95% CI 0.42–0.69; P<0.0001) with the validated and clinically used risk model CAPRA-S [84,85]. The CAPRA-S
score, which is based on pre-operative PSA and pathologic parameters determined at the time of surgery, was de-
veloped to provide clinicians with information aimed to help predict disease recurrence, including BCR, systemic
progression, and PCSM and has been validated in US and other populations [84,85]. This takes account of preop-
erative PSA, pathologic Gleason score, the presence or absence of seminal vesicle invasion (pT3b), positive surgical
margins, extra- capsular extension (pT3a)/lymph node positivity within a multivariable Cox proportional hazards
statistical model.
Interestingly, when assessing the hazard ratio (HR) compared with the continuous ‘PDE4D7 score’ we uncov-
ered [71] a linear increase in risk with decreasing ‘PDE4D7 score’ for score values lying between 2 and 5. However,
at PDE4D7 scores <2, then the risk of post-surgical progression increases steeply [71]. This is also evident in the
Kaplan–Meier survival curves where patients that are grouped within the lowest ‘PDE4D7 scores’ category exhibit
the highest risk of disease recurrence (Figure 4A). Using logistic regression analysis we then combined the CAPRA-S
scorewith the continuous ‘PDE4D7 score’. Testing thismodel usingROCcurve analysis, we noticed a 4–6% significant
improvement in AUC compared with the CAPRA-S alone for both 2- and 5-year predictions of post-treatment pro-
gression to BCR (Figure 4B). Thuswe evaluated a combinedCAPRA-S& ‘PDE4D7 score’ Cox regression combination
model in Kaplan–Meier survival analysis and compared this with the CAPRA-S score categories alone. Undertaking
this, we confirmed the added value in risk prediction when using amodel the combined ‘PDE4D7&CAPRA-S’ score,
compared with using the clinical metric of CAPRA-S score alone [71].
Subsequent to the diagnosis of prostate cancer, an accurate risk assessment needs to be undertaken before strat-
ification to a defined primary treatment. With this in mind, we set out to see if we could translate the prognostic
use of the ‘PDE4D7 score’ in a pre-surgery situation testing tumour tissue obtained from diagnostic needle biopsy
samples [70]. In this, needle biopsies were performed on 168 patients, from a single diagnostic clinical centre, who
had undergone surgery as a primary treatment. The minimum follow-up period for each patient was 60 months af-
ter this intervention. The clinical co-variates used to adjust the ‘PDE4D7 score’ in the multivariable analysis were
age at surgery, pre-operative PSA, PSA density, biopsy Gleason score, percentage of tumour positive biopsy cores,
percentage of tumour in the biopsy and clinical cT stage. In this we evaluated the utility of the ‘PDE4D7 score’ and
the combined ‘PDE4D7 & CAPRA’ scores compared to the pre-surgical CAPRA score in Cox regression analysis for
biochemical relapse [70].
Evaluating this patient cohort we found [70] that the ‘PDE4D7 score’ was inversely associated with BCR in mul-
tivariable analysis when adjusting for clinical variables (HR = 0.43; 95% CI 0.29–0.63; P<0.0001) as well as for the
clinical CAPRA score (HR = 0.53; 95% CI 0.38–0.74; P=0.0001). Kaplan–Meier analysis demonstrated that, as be-
fore, in a post-surgical setting, the ‘PDE4D7 score’ categories were significantly associated with BCR progression
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Figure 4. The ‘PDE4D7 score’ as a prognostic biomarker in prostate cancer
(A) Kaplan–Meier analysis of the time to PSA relapse (BCR – biochemical recurrence) after prostatectomy of the PDE4D7 score
categories in a surgery study cohort (n=503; logrank P<1.0E-04). PDE4D7 score categories are defined as: PDE4D7 (1–2): PDE4D7
scores (1 to <2); PDE4D7 (2–3): PDE4D7 scores (2 to <3); PDE4D7 (3–4): PDE4D7 scores (3 to <4); PDE4D7 (4–5): PDE4D7 scores
(4–5). The highest PDE4D7 score category (4–5) was used as the reference category. (B) ROC cure analysis of 2-year biochemical
recurrence (BCR) for the incremental value of the PDE4D7 score added to the CAPRA-S score categories by logistic regression
analysis in the study cohort (n=469). The PDE4D7 score was modelled as a continuous variable in the logistic regression. For the
prediction of the 2-year PSA relapse after surgery, the incremental value of PDE4D7 was 6% yielding an AUC of 0.82 in comparison
with 0.76 for the CAPRA-S score category model alone (P=0.0004). (C) Kaplan–Meier analysis of the BCR-free survival in the patient
diagnostic biopsy (n=151) cohort of a CAPRA & PDE4D7 score combination model. The CAPRA & PDE4D7 combination model was
created by logistic regression on the independent surgery cohort with complete 5-year follow-up (n=449). The CAPRA & PDE4D7
score categories were defined according to the probability to experience PSA failure after surgery based on the logit(p) function
of the logistic regression model as indicated. (D) ROC curve analysis of 5-year biochemical recurrence (BCR) in the diagnostic
biopsy cohort (n=151) of the CAPRA score versus the CAPRA & PDE4D7 logistic regression model which was developed on the
independent surgery patient cohort with complete 5-year follow-up (n=449). The incremental value of PDE4D7 to the CAPRA
score yielded a 5% increase in AUC (P=0.004). (E) Decision curve analysis in the diagnostic biopsy (n=151) patient cohort of the
net benefit of four different treatment decision strategies for men at risk of disease recurrence within 5 years after surgery. Treatment
strategies were tested for their net benefit across indicated threshold probabilities (0.05 step size) to trigger prostate surgery based
on the probability of future disease recurrence. Figures and legends are adapted from references [70,71].
free survival (logrank P<0.0001) and secondary treatment free survival (logrank P=0.01). We then employed [70] a
combination logistic regression model, which was developed on the previous cohort. This consisted of the combined
‘CAPRA& PDE4D7’ score, demonstrating that patients within the highest combined ‘CAPRA& PDE4D7’ combined
score category have virtually no risk of biochemical progression or transfer to any secondary treatment after surgery
(Figure 4C). This logistic regression model was also evaluated using ROC curve analysis in order to predict 5-year
BCR after surgery. This revealed an increase in AUC of 5% over the CAPRA score alone (AUC= 0.82 vs. 0.77, respec-
tively; P=0.004; Figure 4D). Decision curve analysis of the combined ‘CAPRA & PDE4D7’ score model confirmed
the superior net benefit of using this combined score, compared with either score alone, across all decision thresholds
in order to decide on whether to undertake intervention (e.g. surgery) based on the risk threshold of an individual
patient to experience post-surgical disease progression (Figure 4E).
Conclusions
Disease severity and prognostic outcome vary considerably between incidences of prostate cancer. Indeed, many
prostate cancers present as a slowly progressive or even as a non-progressive indolent disease that are unlikely to
elicit either significant morbidity or death. There has thus been considerable concern that unnecessary harm is done
to patients as a result of over-diagnosis and over-treatment with radiotherapy and radical prostatectomy. Indeed,
there has been a move to AS as a management strategy to monitor disease progression in order to avoid or delay
potential harm to low-risk patient groups [86,87]. However, it is becoming increasingly evident that such a close
surveillance regime comes with substantial challenges concerning both its clinical implementation and as regarding
patient compliance [10,88,89]. In this context, the identification of accurate and reliable prognostic biomarkers is key
in further personalizing treatment strategy and better defining the risk of disease progression.
Here we present a summary of the scientific and clinical research on the cyclic AMP degrading phosphodiesterase
PDE4D7 long isoform in the development of a novel, clinically relevant and personalized prognostic biomarker as-
say for prostate cancer (InformMDx™). This progressed from initial in vitro observations and characterization using
cell lines and xenograft material, through to clinical validation on patient cohorts with longitudinal pathology and
biological outcomes. Specifically, we have shown that PDE4D7 transcript abundance is inversely associated with in-
creasingly aggressive states of prostate cancer. Thus, for patients with low ‘PDE4D7 scores’, the risk of post-surgical
disease progression increases steeply, while risk decreases markedly for those patients with high ‘PDE4D7 scores’. The
predictive nature of this personalized assessment can be further enhanced through combining the ‘PDE4D7 score’
with the CAPRA clinical-biased scoring system [71]. Thus the ‘PDE4D7 score’ provides a robust readout that enables
more accurate patient risk stratification, yielding a clinically effective prognostic test poised to have significant clini-
cal impact for pre-surgical risk stratification. In particular, the PDE4D7 stratification biomarker has potential utility
in selecting men with very minimal (or virtually no) risk of progressive disease for inclusion to AS, thus reducing the
burden that both AS and inappropriate therapeutic intervention place on both the patient and the healthcare system.
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In light of the significant literature that connects cAMP signalling and the molecular hallmarks of advancing
prostate cancer [36,37,39,40,51,53,58], the correlation between decreased PDE4D7 expression and the progression
of prostate cancer suggests that PDE4D7 activity might well influence the underlying cellular pathology. These clin-
ical correlates prompt a need to uncover the precise consequences of how altered PDE4D7 expression in various
states of the disease has an impact on cellular pathology and, indeed, whether PDE4D7 might provide a potential
therapeutic target. Thus, employing the ‘PDE4D7 score’ to stratify patients might have use not only for directing in-
dividuals to particular therapy options that are currently available, but also to stimulate the search for novel treatment
options and even novel therapeutics for patients having low PDE4D7 levels associated with recurring and progressive
forms of prostate cancer. In this regard, during the last decade the treatment landscape of metastatic and/or CRPC
has changed substantially and a number of additional therapeutic options for systemic therapies are available today
[90,91]. However, aside from examples in the adoptive immune cell therapy space [92], newly developed therapeutics
have continued to centre around modulators of AR activity [93,94]. As time-dependent resistance to various of these
novel therapies is now emerging [95], therapeutics aimed at novel molecular targets are urgently required. Indeed,
it may be that positive modulation of PDE4D7 activity, or signalling events associated with it, might present an op-
portunity to develop novel therapeutic options for use alongside PDE4D7 as a target matched, clinically validated,
companion biomarker.
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